Clinical Trial

NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Fixed dose NT219 weekly plus pembrolizumab every 3 weeks or cetuximab weekly to be continued until progression, unacceptable toxicity, or investigator or participant decision.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06-12 -> 2030-02-01 2026-07-03
notable Primary completion moved earlier: 2030-02 -> 2026-06-12 2026-06-23
Trial Details
NCT Number NCT06919666
Lead Sponsor University of Colorado, Denver
Collaborators: Purple Biotech Ltd.
Conditions Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Enrollment 29 participants
Start Date 2025-06-12
Primary Completion 2030-02-01 (estimated)
Study Completion 2031-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-02